Health
Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials – News-Medical.net
Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics…
-
Business21 hours agoTop broker gives its verdict on Coles shares after 25% rise
-
Noosa News21 hours agoAndrew Burow: Link to alleged attacker uncovered in suspected murder of Kelvin Grove father
-
Business21 hours ago2 strong ASX ETFs to buy and hold forever
-
Business22 hours agoIs Nvidia’s increasing reliance on “Customer A” and “Customer B” a red flag for the AI growth stock?